|
Epigenetics
|
7
|
Resverlogix Corp.
|
Feb 12, 2022 05:13PM
|
|
Re: Not out of the woods yet with COVID-19
|
3
|
Resverlogix Corp.
|
Feb 18, 2022 03:47PM
|
|
Re: Not out of the woods yet with COVID-19
|
6
|
Resverlogix Corp.
|
Feb 19, 2022 03:48PM
|
|
Re: Study results?
|
2
|
Resverlogix Corp.
|
Mar 05, 2022 05:50PM
|
|
Re: New treatment for COVID-19 discovered in human skin cells.
|
7
|
Resverlogix Corp.
|
Mar 11, 2022 09:21AM
|
|
Re: So I was able to finally set up a one on one meeting with...
|
6
|
Resverlogix Corp.
|
Mar 16, 2022 11:55AM
|
|
Re: RVX Board Thoughts Mar 18 2022 – Wishful Thinking
|
6
|
Resverlogix Corp.
|
Mar 19, 2022 05:43PM
|
|
Self Financing
|
2
|
Resverlogix Corp.
|
Apr 01, 2022 06:53PM
|
|
Re: Self Financing
|
2
|
Resverlogix Corp.
|
Apr 02, 2022 09:59AM
|
|
Re: FDA approves "empagliflozin" for reducing risk of cardiovascular death, hospitalization among adult HFpEF patients
|
5
|
Resverlogix Corp.
|
Apr 05, 2022 11:28AM
|
|
Re: Veru vs Resverlogix
|
9
|
Resverlogix Corp.
|
Apr 15, 2022 10:58AM
|
|
Extension of debenture!
|
2
|
Resverlogix Corp.
|
Apr 19, 2022 08:45PM
|
|
Re: Resverlogix Announces One-Year Extension of Debenture
|
3
|
Resverlogix Corp.
|
Apr 21, 2022 04:22PM
|
|
Re: New Apabetalone Fabry Disease Publication
|
7
|
Resverlogix Corp.
|
Apr 26, 2022 09:27AM
|
|
Re: New Apabetalone Fabry Disease Publication
|
2
|
Resverlogix Corp.
|
Apr 27, 2022 10:20AM
|
|
Re: New Apabetalone Fabry Disease Publication
|
5
|
Resverlogix Corp.
|
Apr 29, 2022 01:50PM
|
|
Latest News
|
1
|
Resverlogix Corp.
|
May 10, 2022 05:17PM
|
|
Type C Meeting
|
|
Resverlogix Corp.
|
May 12, 2022 09:09AM
|
|
Re: Type C Meeting
|
2
|
Resverlogix Corp.
|
May 12, 2022 10:00AM
|
|
Re: Q1- March 31, 2022 on SEDAR
|
2
|
Resverlogix Corp.
|
May 16, 2022 10:21AM
|
